C. Onal Et Al. , "The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma," CLINICAL & TRANSLATIONAL ONCOLOGY , vol.24, no.8, pp.1533-1541, 2022
Onal, C. Et Al. 2022. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma. CLINICAL & TRANSLATIONAL ONCOLOGY , vol.24, no.8 , 1533-1541.
Onal, C., HÜRMÜZ, P., Guler, O. C., YAVAŞ, G., TİLKİ, B., Oymak, E., ... Yavas, C.(2022). The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma. CLINICAL & TRANSLATIONAL ONCOLOGY , vol.24, no.8, 1533-1541.
Onal, Cem Et Al. "The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma," CLINICAL & TRANSLATIONAL ONCOLOGY , vol.24, no.8, 1533-1541, 2022
Onal, Cem Et Al. "The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma." CLINICAL & TRANSLATIONAL ONCOLOGY , vol.24, no.8, pp.1533-1541, 2022
Onal, C. Et Al. (2022) . "The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma." CLINICAL & TRANSLATIONAL ONCOLOGY , vol.24, no.8, pp.1533-1541.
@article{article, author={Cem Onal Et Al. }, title={The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma}, journal={CLINICAL & TRANSLATIONAL ONCOLOGY}, year=2022, pages={1533-1541} }